AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.
17 December 2021 in Journal of Ankara University Faculty of Medicine